JCO Oncology Advances
@JCOOA_ASCO
Followers
131
Following
19
Media
5
Statuses
55
Conquering cancer | Open-access journal disseminating high-quality early phase and trial-adjacent studies, to advance care globally. Part of @JCO_ASCO family.
Joined June 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study. Read the full article.
ascopubs.org
PURPOSEPLATFORM is an adaptive phase II study assessing maintenance therapies in advanced esophagogastric adenocarcinoma (OGA). We evaluated the role of capecitabine plus a vascular endothelial...
0
0
0
First in-person meeting for our journal editors! So much energy and great discussion about the future of JCO Oncology Advances. Thrilled to connect face-to-face.
0
2
11
Consistent TROP-2 Positivity in Tracheobronchial adenoid-cystic carcinoma: expanding antibody-drug conjugates opportunities in Rare Thoracic Tumor. Read the full article.
ascopubs.org
PURPOSETracheobronchial adenoid cystic carcinoma (TACC) is a rare malignancy arising from the submucosal glands of the trachea or main bronchi. Similar to its more common salivary gland counterpart...
0
2
4
Terrific commentary from @gagan_brar24 @cityofhope w mentorship from @aparna1024 @MGHCancerCenter on a recent manuscript in @JCOOA_ASCO assessing use of ctDNA in #Vietnam. Full paper here: https://t.co/eqQlIS18u1
1
13
31
SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low–Tumor Burden Follicular Lymphoma. Read the full article.
ascopubs.org
0
0
3
Peripheral Blood Stem Cell Mobilization and Collection Practices in Pediatric Patients with Central Nervous System and Solid Tumors. Read the full article.
ascopubs.org
PURPOSEHigh-dose chemotherapy followed by autologous stem-cell transplant is an essential component of treatment for pediatric patients with solid tumors. However, the optimal strategy for peripheral...
0
0
0
Great energy at our 1st @JCOOA_ASCO editors meeting at @ASCO HQ. Proud to advance cancer research, and support rapid, impactful publication. Submit your Brief Reports, Phase I/II Trials, Trials in Progress & more.. #JCOOA #CancerResearch #Oncology @PamelaKunzMD
1
9
46
👏 Congrats @VivekSubbiah & team on their important study in @JCOOA_asco 👉 how @US_FDA Project Optimus is transforming early-phase oncology trials — shifting focus from “maximum tolerated dose” to smarter, patient-centered designs👉huge step forward for cancer research!
🚨 Hot off the press in @ASCO journal @JCOOA_ASCO 👉Pleased to share our study 👉 "Impact of FDA Project Optimus Guidance on Design of Early-Phase Clinical Trials" 📊 Analysis of 367 phase I #oncology trials (2021-2024) reveals Project Optimus is transforming cancer drug
1
5
18
Impact of Food and Drug Administration (FDA) Project Optimus guidance on design of early phase clinical trials. Read the full article.
ascopubs.org
PURPOSEFirst-in-human phase I trials serve as a critical bridge from laboratory research to clinical application. The US Food and Drug Administration (FDA) Project Optimus, launched in 2021, aims to...
0
0
0
Real-world utilization of circulating tumor DNA: A retrospective analysis in Vietnam. Read the full article.
ascopubs.org
0
0
0
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches. Read the full article. https://t.co/uKQVOjcLAH
#ColorectalCancer
ascopubs.org
There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However,...
0
0
0
Trials in Progress: The Power of Timely Cancer Clinical Trial Communication. Read the full article.
ascopubs.org
0
0
0
Serum GDF-15 levels are markedly elevated in pancreatic cancer patients compared to healthy controls. 🔹 Mean GDF-15: – 598 pg/mL in controls vs. 2,505 pg/mL in PC patients – Higher in unresectable cachectic PC (3,029 pg/mL) vs. resectable disease (2,088 pg/mL, P = .0227) 🔹
2
8
20
Phase Ib Trial of Batiraxcept in Combination With Nab-Paclitaxel and Gemcitabine for Previously Untreated Advanced Pancreatic Cancer. Read the full article.
ascopubs.org
PURPOSEIncreased anexelekto (AXL) pathway signaling in pancreatic cancer can increase cellular invasion, migration, proliferation, and protumoral infiltration of tumor-associated macrophages and...
0
0
0
🎉 We're excited to announce that #JCOOA is now indexed in #DOAJ! This milestone recognizes our commitment to high-quality, peer-reviewed, open access oncology research. A huge thank you to our authors, reviewers, and readers for their support. https://t.co/yIZAaJzHWW
#OpenAccess
ascopubs.org
0
0
0
Growth Differentiation Factor 15 Serum Levels in Pancreatic Cancer. Read the full article. https://t.co/d5Eo1o6Ysi
#pamcsm
ascopubs.org
PURPOSECancer cachexia is a prevalent condition in pancreatic cancer (PC), affecting up to 80% of patients. There is an urgent need to understand this syndrome and identify potential targetable...
0
0
0
Patterns of Homologous Repair Deficiency and BRCA1/2 Testing of Ovarian and Breast Cancers: A Real-World Study of Patients in Community Health Settings in the United States. Read the full article. https://t.co/svsMVDWBaW
#bcsm #OvarianCancer
ascopubs.org
PURPOSETesting to measure homologous repair deficiency (HRD) in certain cancers can identify patients who may benefit from poly(ADP-ribose) polymerase inhibitors. We examined real-world patterns and...
0
0
0
JCO Oncology Advances is an open-access journal for early-phase trials and articles on topics like quality of life and supportive care. Publish your original reports and trials with us today: https://t.co/E40K0jP3Am
#JCOOA
0
0
0
ChatGPT performance as patient-facing triaging tool in oncology. Read the full article.
ascopubs.org
PURPOSEThis study assessed the diagnostic accuracy and medical appropriateness of a publicly available large language model (LLM) in triaging common clinical scenarios in breast oncology.METHODSFrom...
0
1
1
Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Read the full article.
ascopubs.org
PURPOSEThe impact of insurance status on survival outcomes in patients receiving first-line systemic therapy for metastatic renal cell carcinoma (mRCC) has not been explored. Herein, we aimed to...
0
3
9